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Case History
A Novel Activating Mutation in Transmembrane Helix 6 of
the Thyrotropin Receptor as Cause of Hereditary
Nonautoimmune Hyperthyroidism
Benjamin U. Nwosu,1 Loukas Gourgiotis,2 Marvin C. Gershengorn,2 and Susanne Neumann2
Constitutively-activating germline mutations of the thyrotropin receptor (TSHR) gene are very rare and are
considered the cause of hereditary nonautoimmune hyperthyroidism. We describe four affected individuals
from a Caucasian family: a mother and her three children, and an unaffected father. The mother and her first
two children presented in a similar manner: lifelong histories of heat intolerance, hyperactivity, fast heart rate,
reduced energy, increased appetite, and scrawny build. They all developed goiter in childhood and showed a
suppressed TSH and elevated thyroxine (T4). The last child, a 12-year-old female, presented with no clinical
symptoms or palpable neck mass, but with a suppressed TSH, elevated T4 and thyromegaly detected by ul-
trasound. Mutation analysis of the TSHR gene in all family members revealed a novel heterozygous germline
mutation resulting in the substitution of phenylalanine (TTC) by serine (TCC) at codon 631 in transmembrane
helix 6 in the mother and all three children. Functional characterization of this germline mutation showed con-
stitutive activation of the Gs-mediated cyclic adenosine monophosphate (cAMP) pathway, which controls thy-
roid hormone production and thyroid growth. Molecular characterization of F631S demonstrates that this ac-
tivating mutation plays a key role in the development of hereditary hyperthyroidism in this family although
the timing of onset of clinical manifestations in the subjects may depend on other, as yet unidentified, factors.
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Introduction
THE THYROTROPIN RECEPTOR (TSHR) belongs to the super-family of seven transmembrane-spanning receptors,
specifically to the subfamily of glycoprotein hormone re-
ceptors. Binding of the ligand, thyrotropin (TSH), to its re-
ceptor leads to activation of the Gs-mediated cyclic adeno-
sine monophosphate (cAMP) pathway and at higher
concentrations of the Gq-mediated phospholipase C-inosi-
tol phosphate (IP) pathway (1). As activation of the phos-
pholipase C cascade requires 10 times higher TSH concen-
trations, it is generally accepted that cAMP activation is the
major pathway that controls growth and function of thyro-
cytes (2,3). The phospholipase C pathway is involved in con-
trol of iodination and thyroid hormone synthesis (4).
Numerous gain-of-function mutations of TSHR that cause
constitutive (ligand-independent) activation of the cAMP
cascade have been identified in different thyroid patholo-
gies (2,3,5) (www.uni-leipzig.de/innere/tsh/). For a few
mutants, constitutive activation of both cAMP and phos-
pholipase C cascades has been reported (6). Somatic acti-
vating mutations of TSHR have been identified as the cause
of solitary toxic adenomas and multinodular goiter (2,3,6).
Somatic mutations also have been reported in thyroid car-
cinomas, albeit much more infrequently (7–9). Germline
activating TSHR mutations cause congenital nonautoim-
mune hyperthyroidism, which is a rare inherited condition
(2,5,10). These heterozygous autosomal dominant germ-
line mutations underline convincingly the causal impact of
TSHR mutations for the pathogenesis of hyperthyroidism.
The prominent clinical characteristics of nonautoimmune
hyperthyroidism are autosomal dominant transmission, a
positive family history of hyperthyroidism, and hyperplas-
tic goiter with an early occurrence of the disease and re-
currence after medical treatment (11). The age of onset of
hyperthyroidism varies, which may be explained by differ-
1University of Massachusetts Medical School, Worcester, Massachusetts.
2Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
Maryland.
ences in environmental factors, in particular iodine intake,
or might be the result of other genetic components. Com-
monly, familial nonautoimmune hyperthyroidism is con-
fused with Graves’ disease, an autoimmune disorder caused
by activating TSHR antibodies (12,13). However, familial oc-
currence of hyperthyroidism in the absence of TSHR anti-
bodies is highly suggestive of familial nonautoimmune hy-
perthyroidism resulting from a constitutively activating
TSHR germline mutation. Thyroid ablation (surgery and/or
radioiodine) is recommended as therapy because there is no
likelihood of spontaneous remission of hyperthyroidism (2).
Detection and molecular analysis of germline mutations in
families with nonautoimmune hyperthyroidism has an im-
portant clinical impact with respect to genetic counseling
and presymptomatic diagnosis of hyperthyroidism in chil-
dren from affected families.
The first case of nonautoimmune hyperthyroidism was de-
scribed in 1982 in the Nancy family in which 9 of the 34 mem-
bers studied were found to be thyrotoxic with a diffusely en-
larged goiter and no signs of Graves’ disease or presence of
serum autoantibodies (14). Molecular analysis revealed a het-
erozygous germline mutation that leads to a valine to ala-
nine substitution at amino acid position 509 in transmem-
brane helix (TMH) 3 of TSHR (10). Subsequently, 19 germline
TSHR mutations in 12 families and 7 children with sporadic
occurrence have been reported (5) (www.uni-leipzig.de/
innere/tsh/). Interestingly, the majority of germline mu-
tations (63%) is not observed in toxic thyroid nodules. This
is compatible with the observation that hereditary mutations
cause a less severely affected phenotype, with a marginal ef-
fect on reproductive fitness (2,10,15,16). Because of limited
cases of germline mutations, no systematic study has yet
been performed to demonstrate a correlation between geno-
type and phenotype. Such an approach might also be lim-
ited in its conclusions due to the influence of environmental
and other genetic factors. Nevertheless, identification and
molecular characterization of naturally occurring mutants
has led to significant progress in diagnosis of nonautoim-
mune hyperthyroidism and in our understanding of the
TSHR activation mechanism.
In this study, we report a novel activating TSHR germline
mutation at amino acid position 631 in TMH6 in a mother
and her three children, all affected by hyperthyroidism (Fig.
1A). Subsequent functional in vitro characterization of the
mutant F631S revealed constitutive activation of the cAMP
regulatory cascade demonstrating that this mutation plays a
key role in development of hereditary hyperthyroidism in
this family.
Case Report
The propositus is a 47-year-old Caucasian female who has
had lifelong symptoms suggestive of hyperthyroidism. She
had been born to a 30-year-old G3 P2 female. Her birth
weight was 2200 g. She had no perinatal complications and
achieved normal milestones for age. She recalls that as a
youngster she had always felt that she was “burning up on
the inside” and describes herself as being scrawny, sweaty,
with a fast heart rate, and hyperactive demeanor in associa-
tion with reduced energy, increased appetite, and intoler-
ance to heat. Her thyroid gland progressively increased in
size. At age 42 years, she presented to a tertiary care hospi-
tal with a neck mass and prominent eyes. Her physical ex-
amination revealed proptosis, goiter, smooth skin, mild
tremor of the extremities and brisk deep tendon reflexes. Her
thyroid function test (TFT) results were consistent with hy-
perthyroidism (Table 1). Her radioactive iodine uptake was
78% (normal, 10%–35%) in 24 hours. A radioactive iodine
scan revealed diffuse uptake throughout both lobes of a
mildly enlarged gland with a firm smooth hypofunctioning
nodule in the region of the isthmus. She had a fine-needle
aspiration biopsy (FNAB) of the nodule, which was consis-
tent with a benign colloid nodule. She was diagnosed with
Graves’ disease and placed on methimazole, which she tol-
erated poorly. Subsequently, she had radioactive iodine ab-
lation with 6 mCi of 131I. Five months later, her TFTs nor-
malized (Table 1). She was started on levothyroxine 50 g
daily. Despite normalization of serum thyroxine levels, she
complained of fatigue, muscle aches, and inability to lose
weight. Levotriiodothyronine was added empirically and
she was maintained on levotriiodothyronine 10 g and
levothyroxine 75 g daily.
The patient’s family history revealed that she is one of
three children. She says that both her father and paternal
grandmother had “bug eyes,” but they were never evaluated
for any endocrine dysfunction. She has two brothers who ap-
pear normal. She is married and has three children. Her first
child, a 24-year-old male, was diagnosed with hyperthy-
roidism at 19 years of age. He had similar lifelong symptoms
as his mother but no visible neck mass. He was born at 34
weeks of gestation. He weighed 2200 g and was 50.8 cm long.
His TFTs are presented in Table 1. His neck ultrasound
showed an enlarged thyroid gland primarily in the antero-
posterior and transverse directions. The right lobe measured
4.8  2.0  2.2 cm, and the left lobe 5.3  2.3  2.6 cm. Thy-
roid parenchyma was diffusely patchy and micronodular in
echotexture, with scattered millimeter-sized nonspecific ap-
pearing nodules in both lobes of the thyroid gland. He was
started on methimazole 10 mg three times daily. Three
months later, he normalized his T4 level but TSH remained
suppressed at less than 0.05 U/mL.
The proband’s second child is an 18-year-old daughter
who was diagnosed with hyperthyroidism at 11 years of age.
She was born at 34 weeks of gestation. Her birth weight was
2130 g and she was 50.8 cm long. She has had similar life-
long symptoms as her mother and brother. Her TFTs are pre-
sented in Table 1. She had an enlarged thyroid gland with a
neck ultrasound revealing a multinodular goiter with sev-
eral dominant-sized complex nodules in both lobes. The right
lobe measured 8.5  2.4  3.7 cm, and the left lobe measures
8.2  2.7  3.1 cm. A multiloculated nodule, measuring
3.0  1.5  2.0 cm with internal solid components, was iden-
tified in the lower pole of the left lobe. Radioactive iodine
scan showed a uniform bilobar uptake with the exception of
two small nodules, one in each lobe. Her 6-hour thyroid up-
take was 100%. She was started on methimazole, which was
discontinued because of side effects.
The proband’s last child is a 12-year-old daughter with
cerebral palsy who was diagnosed with hyperthyroidism at
10 years of age during a follow-up. She was born at 30 weeks
of gestation. She weighed 1310 g, and measured 43.2 cm. She
has neither a goiter nor any of the hyperthyroid symptoms
shown by her mother and siblings. Her physical examina-
tion revealed a wide pulse pressure, smooth skin, and
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slightly exaggerated tendon reflexes. Her TFTs are presented
in Table 1. Her neck ultrasound showed a normal thyroid
gland size and contour with no nodularity. She was started
on 5 mg methimazole daily. She complained of muscle aches,
pains, and weight gain, necessitating the reduction of her
dose to 2.5 mg every other day. TSHR antibodies were neg-
ative in the proband and all three children. The proband had
positive antithyroidal antibodies (anti-Tg 200 IU/mL [nor-
mal,  40], anti-TPO 105 IU/mL [normal,  35]).
The study was approved by the Institutional Review
Board of the Intramural Division of the National Institute of
Diabetes and Digestive and Kidney Diseases and informed
consent was obtained from all family members.
Materials and Methods
DNA analysis of the TSHR gene
Because of the familial occurrence of hyperthyroidism,
blood samples were taken from the parents and the three
children. Genomic DNA was extracted from the patients’ pe-
ripheral blood leukocytes using the QIAamp DNA Blood
Midi Kit (QIAGEN, Valencia, CA). Two overlapping frag-
ments of exon 10 of the TSHR were amplified by polymerase
chain reaction (PCR) using YieldAce Hotstart DNA poly-
merase (Stratagene, La Jolla, CA) according to the instruc-
tions of the manufacturer. We used PCR primers for exon 10
published by De Roux et al. (17). The PCR products were
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FIG. 1. Analysis of the TSHR gene in all family members.
A: Pedigree of the family. All affected family members are
indicated by filled symbols. B: Sequencing of one polymerase
chain reaction (PCR) fragment of exon 10 revealed an iden-
tical heterozygous TSHR mutation in the children and their
mother at nucleotide position 1892, where a T is substituted
by a C, resulting in substitution of phenylalanine (TTC) with
serine (TCC) at residue 631 of the TSHR. The numbering of
the pedigree symbols and the sequences correspond to each
other.
purified using the MinElute PCR Purification kit (QIAGEN,
Valencia, CA) and sequenced using the PCR primers. Se-
quencing reactions were performed by MWG Biotech, Inc.
(High Point, NC).
Site-directed mutagenesis
Human TSHR cDNA in expression vector pcDNA3.1 was
obtained from the UMR cDNA Resource Center
(www.cdna.org) and used as template for mutagenesis. The
F631S mutant was generated using the QuikChange II XL
Site-Directed Mutagenesis Kit (Stratagene) according to the
instructions of the manufacturer. Sequence of mutated TSHR
was verified by dideoxy sequencing.
Cell culture and transfection
HEK (human embryonic kidney) 293 EM cells (18) were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum, 100 U/mL penicillin,
and 10 g/mL streptomycin (Life Technologies Inc.) at 37°C
in a humidified 5% CO2 incubator. One day before trans-
fection, the cells were seeded in 24-well dishes (0.5  105
cells per well). After 24 hours, cells were transiently trans-
fected with 0.2 g receptor expression vector per well us-
ing FuGENETM6 reagent (Roche, Basel, Switzerland). Mock
transfections were performed with empty expression vector
pcDNA3.1. All assays were performed 48 hours after trans-
fection.
Determination of cell surface expression 
by FACS analysis
After transfection, cells were cultured for 48 hours, har-
vested using 1 mM ethylenediaminetetraacetic acid (EDTA)
and 1 mM ethyleneglycoltetraacetic acid (EGTA) in phos-
phate-buffered saline (PBS) and transferred to Falcon 2058
tubes. Cells were washed once with PBS containing 0.1%
bovine serum albumin (BSA) and 0.1% NaN3 (binding
buffer), incubated for 1 hour with a 1:200 dilution of mouse
anti-human TSHR antibody (Serotec, MCA1281, Clone num-
ber 2C11) in binding buffer, washed twice, and incubated for
1 hour in the dark with a 1:200 dilution in binding buffer of
an Alexa Fluor 488-labeled F(ab’)2 fragment of goat anti-
mouse IgG (Molecular Probes, Eugene, OR). Before FACS
analysis (FACS Calibur, BD Biosciences, San Jose, CA), cells
were washed twice and fixed with 1% paraformaldehyde.
Receptor expression was estimated by fluorescence intensity
and transfection efficiency was measured as the percentage
of fluorescent cells.
cAMP accumulation assay
Measurement of cAMP accumulation was performed 48
hours after transfection of HEK 293 cells using a cAMP Bio-
trak Enzymeimmunoassay according to the instructions of
the manufacturer (Amersham Biosciences, Piscataway, NJ).
Measurement of IP formation
Transfected HEK 293 cells were incubated with 2 Ci/mL
of [myo-3H] inositol (18.6 Ci/mmol) (Amersham) for 18
hours. Thereafter, cells were preincubated with serum free
DMEM containing 10 mM LiCl for 15 minutes. Stimulation
with TSH was performed with the same medium supple-
mented with 100 mU/mL TSH for 1 hour. Basal and TSH-
induced increases in intracellular IP levels were determined
by anion exchange chromatography as described (19). IP val-
ues are expressed as the percentage of radioactivity incor-
porated from 3[H]-inositolphosphates over the sum of ra-
dioactivity incorporated in IPs and phosphatidyl inositols.
Results
Identification of TSHR mutation
Direct sequencing of exon 10 of the TSHR gene of all fam-
ily members led to identification of a heterozygous T to C
transition at nucleotide position 1892. This heterozygous mu-
tation results in the substitution of a highly conserved pheny-
lalanine (TTC) by serine (TCC) at codon 631 (F631S) in
TMH6. The mutation was found in the mother and all her 3
three children; however, it was absent in their unaffected fa-
ther (Fig. 1A and B).
Functional characterization of the novel TSHR 
germline mutation
HEK 293 cells were transiently transfected with the wild
type (wt) TSHR and the F631S mutant. Cells surface expres-
sion for the F631S mutant was reduced by 60% compared to
TSHR (Fig. 2). Basal and TSH-stimulated cAMP and IP pro-
duction were measured. F631S showed constitutive activa-
NWOSU ET AL.508
TABLE 1. HORMONE STATUS, DURATION OF PREGNANCY, AND BIRTH WEIGHT
DUE TO AUTOSOMAL-DOMINANT NONAUTOIMMUNE HYPERTHYROIDISM
TSH Total T4 Free T4 Total T3 Pregnancy
(NR 0.28– (NR 4.5–12.5 (NR 0.58–1.64 (NR 80–213 duration Birth weight
3.89 U/mL) g/dL) ng/dL) ng/dL) (weeks)a (g)
Mother 0.04 20.63 434 2200
(before RAI)
Mother 0.41 0.79
(post-RAI)
Son 0.05 21.70 34 2200
First daughter 0.01 14.20 5.32 592 34 2130
Second daughter 0.04 19.10 2.32 418 30 1310
aPremature birth: 37 weeks or less; normal range of birth weight: 2720–4530 g; 
RAI, radioactive iodine; TSH, thyrotropin; T3, triiodothyronine; T4, thyroxine.
tion of the Gs-mediated adenylyl cyclase-cAMP pathway. Ba-
sal cAMP production of F631S was sevenfold higher than ba-
sal TSHR activity (Fig. 3A). TSH-induced cAMP production
was not affected by the F631S mutant. In contrast, basal Gq-
mediated inositol phosphate formation induced by F631S
was comparable to TSHR. However, the TSH-induced IP re-
sponse was reduced for F631S (30% of maximum TSHR re-
sponse) (Fig. 3B), which might be partly explained by the
low cell surface expression of this mutant.
Discussion
Constitutive activation of TSHR is involved in hyper-
functioning thyroid adenomas and autosomal dominant,
nonautoimmune hyperthyroidism caused by heterozygous
somatic or germline mutations, respectively. Familial nonau-
toimmune hyperthyroidism is a rare disorder, with an inci-
dence of less than 1% in patients with juvenile hyperthy-
roidism (20). Until now, 18 constitutively activating germline
mutations of TSHR were reported in cases of hereditary and
sporadic nonautoimmune hyperthyroidism (5). All gain-of-
function germline mutations were identified in exon 10 en-
coding the serpentine domain of TSHR with exception of
S281N in exon 9 (21), which encodes part of the large
ectodomain. One germline mutation at amino acid position-
183 in the ectodomain did not lead to constitutive TSHR ac-
tivation. In this case, hereditary gestational hyperthyroidism
was caused by hypersensitivity of the mutated TSHR to
chorionic gonadotropin (22). The majority of germline mu-
tants (44%) has been identified in TMH6 and 7 of TSHR
(www.uni-leipzig.de/innere/tsh/). Herein we report a
novel heterozygous germline mutation resulting in substi-
tution of phenylalanine by serine at codon-631 (F631S) in
TMH6 of TSHR in the mother and all three children. Con-
stitutive activation of the Gs-mediated cAMP pathway by
F631S demonstrates that this novel activating germline mu-
tation plays a key role in the development of hereditary hy-
perthyroidism in this Caucasian family. Four other amino
acid substitutions are known at this highly conserved posi-
tion: F631I, L, C and V. F631I, V and C have been detected
in hyperfunctioning thyroid nodules (23-26). F631L was
found in both hyperfunctioning thyroid adenomas and con-
genital hyperthyroidism (27,28). F631I has not yet been func-
tionally characterized. Mutants F631L, C, and V lead to con-
stitutive activity of TSHR with regard to cAMP production,
however, no constitutive activation of the phospholipase C
pathway was observed. The novel F631S mutant identified
in this family also did not exhibit an increase of basal inos-
itol phosphate production, however, in contrast to the other
described mutants, we observed impairment of TSH-in-
duced activation of this pathway (only 30% of maximum
TSHR response). This difference among the mutant recep-
tors might be partly explained by diverse helical conforma-
tions caused by different mutants at amino acid position 631.
However, because all mutants were described in single stud-
ies and assays for determination of functional characteristics
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FIG. 2. Cell surface expres-
sion of F631S mutant. HEK 293
cells were transiently transfected
with pcDNA3.1 vector (control),
TSHR or F631S. A: Cell surface
expression was measured using
fluorescence-activated cell sorter
(FACS) analysis. Fluorescence
intensity is expressed in arbi-
trary units as function of cell
number plotted on logarithmic
scale. B: The fluorescence signal
for the TSHR was set at 100%
and the F631S mutant is ex-
pressed as percent of TSHR. Cell
surface expression is decreased
for the F631S mutant compared
to TSHR. The data represent the
mean  standard deviation (SD)
of duplicate determinations in
two separate experiments.
vary, only a direct comparison of all described mutants in
one study might allow precise conclusions with regard to
pharmacologic and structural differences.
The strong reduction in cell surface expression by F631S
in comparison to TSHR could be the result of abnormal fold-
ing of the receptor supporting the idea of changes in helical
conformation. It has been shown that a mutated constitu-
tively active TSHR or angiotensin II AT (1A) receptor ex-
hibited increased internalization in absence of the ligand
(29,30). Moreover, constitutive downregulation and desensi-
tization resulting in low expression levels was demonstrated
for several 7TMRs (31). These might be alternative explana-
tions for the reduced cell surface expression of the F631S mu-
tant.
TMH6 is a “hot spot” domain for constitutively activating
mutations. F631 belongs to a cluster of five consecutive
residues (L629–D633) for which several constitutive activat-
ing amino acid substitutions are described (28). Intramolec-
ular interactions between TMH5, 6, and 7 are critical for
stabilizing the inactive receptor conformation (32–36). Con-
stitutive activity by mutations is proposed to occur by break-
age of hydrogen bonds between TMH6 and 7 or disturbance
of hydrophobic interactions between TMH5 and 6 leading to
receptor activation (35,37).
Clinical presentation of patients with the same TSHR
germline mutation reveals the absence of a clear correlation
between genotype and phenotype (38). Even within family
members harboring the same mutation phenotypes are vari-
able, suggesting that additional factors are required for full
expression of the phenotype (39,40). Differences in thyrotoxic
manifestations and development of goiter are also present in
the described family. Hyperthyroidism was diagnosed in a
range of 10–19 years of age in the three children. The first
two children are affected by goiter, but the youngest daugh-
ter has not yet developed goiter nor has she shown lifelong
symptoms of hyperthyroidism as her siblings and mother.
This new family case underlines that the same germline mu-
tation can result in phenotypic variations regarding age of
onset, severity of thyrotoxicosis and goiter, and demon-
strates additional dependence of clinical manifestation of
other genetic and/or environmental factors.
Premature birth and low birth weight are two other impor-
tant clinical characteristics which are associated with non-
autoimmune hyperthyroidism caused by activating TSHR
mutations. The mean duration of gestation in patients with
activating germline mutations is significantly lower than in
patients with inactivating TSHR mutations causing congeni-
tal hypothyroidism (41). All three children in our investigated
family were born prematurely and had low birth weight con-
firming this correlation (Table 1). Interestingly, a patient with
congenital hyperthyroidism caused by a germline mutation,
which resulted in the substitution of phenylalanine by leucine
at position 631, was also born prematurely at 32 weeks of ges-
tation with a low birth weigth of 1660 g (27). These observa-
tions suggest that the TSHR might influence the timing of de-
livery by an yet unknown mechanism (41).
In conclusion, an autosomal dominant trait and absence
of TSHR antibodies were the first clinical indications in this
family. DNA analysis and subsequent functional character-
ization of the novel germline mutation F631S allowed us to
diagnose hereditary nonautoimmune hyperthyroidism. This
diagnosis has important implications for current patient
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FIG. 3. Functional characterization of F631 mutant. Basal and thyrotropin (TSH)-stimulated cyclic adenosine monophos-
phate (cAMP; A) and inositol phosphate (IP; B) accumulation in HEK 293 cells expressing TSHR or F631S in the absence
(filled bars) or presence (open bars) of 100 mU/mL bovine TSH. The cAMP data represent the mean  standard deviation
(SD) of triplicate determinations in one representative experiment out of three separate experiments. IP data represent the
mean  range of duplicate determinations in 1 representative experiment of 3 separate experiments.
management in this family as well as for genetic counseling
and presymptomatic diagnosis of hyperthyroidism in sub-
sequent generations.
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